Edward Tenthoff
Stock Analyst at Piper Sandler
(3.57)
# 968
Out of 5,182 analysts
197
Total ratings
45.03%
Success rate
7.18%
Average return
Main Sectors:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KPTI Karyopharm Therapeutics | Reiterates: Overweight | $12 → $8 | $8.66 | -7.62% | 2 | Mar 30, 2026 | |
| GENB Generate Biomedicines | Initiates: Overweight | $24 | $12.80 | +87.50% | 1 | Mar 24, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Overweight | $105 → $110 | $48.79 | +125.48% | 8 | Mar 17, 2026 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $45 → $58 | $35.27 | +64.45% | 3 | Mar 13, 2026 | |
| IBRX ImmunityBio | Reiterates: Overweight | $7 → $12 | $7.44 | +61.29% | 1 | Mar 4, 2026 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $10 → $6 | $1.72 | +248.84% | 1 | Feb 25, 2026 | |
| ARVN Arvinas | Reiterates: Overweight | $16 → $20 | $10.44 | +91.57% | 8 | Feb 25, 2026 | |
| MRNA Moderna | Maintains: Overweight | $63 → $69 | $50.73 | +36.01% | 14 | Feb 23, 2026 | |
| IPSC Century Therapeutics | Maintains: Overweight | $2 → $4 | $2.22 | +80.18% | 9 | Jan 20, 2026 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Overweight | $28 → $37 | $19.79 | +86.96% | 4 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 → $110 | $73.91 | +48.83% | 14 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $8 | $1.91 | +318.85% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $98 → $125 | $84.91 | +47.21% | 5 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 → $23 | $7.84 | +193.37% | 6 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 → $6 | $1.15 | +421.74% | 2 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $449 → $489 | $305.54 | +60.04% | 15 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $12 | $4.44 | +170.27% | 2 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $15 | $10.52 | +42.59% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 | $33.33 | -39.99% | 7 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $7 | $1.89 | +270.37% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $48 | $18.26 | +162.87% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $15.52 | +54.64% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $23.90 | +226.36% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $12.98 | +131.12% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $1.79 | +3,531.28% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $0.97 | +1,961.86% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.23 | +143.90% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $17.70 | -83.05% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.33 | +351.13% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.89 | +164.55% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $4.11 | +2,089.78% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $8.10 | +2,122.22% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $16.95 | +159.59% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $4.84 | +664.46% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40,439,520 → $11,721,600 | $4.88 | +240,196,621.31% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $780.25 | -54.63% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $430.29 | -24.93% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $25 | $10.25 | +143.90% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $44.94 | -19.89% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.40 | +1,685.71% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.61 | +24,490.16% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $751.57 | - | 11 | Feb 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $882 → $1,064 | $16.77 | +6,244.66% | 2 | Apr 15, 2013 |
Karyopharm Therapeutics
Mar 30, 2026
Reiterates: Overweight
Price Target: $12 → $8
Current: $8.66
Upside: -7.62%
Generate Biomedicines
Mar 24, 2026
Initiates: Overweight
Price Target: $24
Current: $12.80
Upside: +87.50%
CRISPR Therapeutics AG
Mar 17, 2026
Reiterates: Overweight
Price Target: $105 → $110
Current: $48.79
Upside: +125.48%
Capricor Therapeutics
Mar 13, 2026
Reiterates: Overweight
Price Target: $45 → $58
Current: $35.27
Upside: +64.45%
ImmunityBio
Mar 4, 2026
Reiterates: Overweight
Price Target: $7 → $12
Current: $7.44
Upside: +61.29%
Cardiff Oncology
Feb 25, 2026
Maintains: Overweight
Price Target: $10 → $6
Current: $1.72
Upside: +248.84%
Arvinas
Feb 25, 2026
Reiterates: Overweight
Price Target: $16 → $20
Current: $10.44
Upside: +91.57%
Moderna
Feb 23, 2026
Maintains: Overweight
Price Target: $63 → $69
Current: $50.73
Upside: +36.01%
Century Therapeutics
Jan 20, 2026
Maintains: Overweight
Price Target: $2 → $4
Current: $2.22
Upside: +80.18%
Monte Rosa Therapeutics
Jan 14, 2026
Reiterates: Overweight
Price Target: $28 → $37
Current: $19.79
Upside: +86.96%
Jan 13, 2026
Reiterates: Overweight
Price Target: $100 → $110
Current: $73.91
Upside: +48.83%
Jan 9, 2026
Maintains: Overweight
Price Target: $6 → $8
Current: $1.91
Upside: +318.85%
Dec 9, 2025
Reiterates: Overweight
Price Target: $98 → $125
Current: $84.91
Upside: +47.21%
Dec 8, 2025
Reiterates: Overweight
Price Target: $16 → $23
Current: $7.84
Upside: +193.37%
Nov 14, 2025
Reiterates: Overweight
Price Target: $5 → $6
Current: $1.15
Upside: +421.74%
Oct 31, 2025
Reiterates: Overweight
Price Target: $449 → $489
Current: $305.54
Upside: +60.04%
Sep 15, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $4.44
Upside: +170.27%
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $10.52
Upside: +42.59%
Jun 16, 2025
Upgrades: Overweight
Price Target: $20
Current: $33.33
Upside: -39.99%
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.89
Upside: +270.37%
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $18.26
Upside: +162.87%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $15.52
Upside: +54.64%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $23.90
Upside: +226.36%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $12.98
Upside: +131.12%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $1.79
Upside: +3,531.28%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $0.97
Upside: +1,961.86%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.23
Upside: +143.90%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $17.70
Upside: -83.05%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.33
Upside: +351.13%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.89
Upside: +164.55%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $4.11
Upside: +2,089.78%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $8.10
Upside: +2,122.22%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $16.95
Upside: +159.59%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $4.84
Upside: +664.46%
May 13, 2022
Maintains: Overweight
Price Target: $40,439,520 → $11,721,600
Current: $4.88
Upside: +240,196,621.31%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $780.25
Upside: -54.63%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $430.29
Upside: -24.93%
May 7, 2021
Downgrades: Neutral
Price Target: $80 → $25
Current: $10.25
Upside: +143.90%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $44.94
Upside: -19.89%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.40
Upside: +1,685.71%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.61
Upside: +24,490.16%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $751.57
Upside: -
Apr 15, 2013
Maintains: Neutral
Price Target: $882 → $1,064
Current: $16.77
Upside: +6,244.66%